Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT926TNQ)

• DOT Name: Synaptonemal complex protein 2-like (SYCP2L)
• Synonyms: SCP-2-like; 145 kDa nucleolar protein homolog; hsNO145
• Gene Name: SYCP2L
• Related Disease:
  Chronic obstructive pulmonary disease
  Allergic rhinitis
  Phospholipid syndrome
• UniProt ID: SYC2L_HUMAN
• Pfam ID: PF18581 ; PF18584
• Sequence:
  MQAKNKDALQPIKEDRTGKAQDDAFWLQSLITDAFHDKGFQKIKEYFQQKESHFPQKYNR
  LLLYRLDRSINKELDKNEFQSVSLLLKCIQRFLVDGLKEDEPLLIRQGLIPKLVSWFERT
  TGILTSEGLASDTSLICVIEDFFDTALIISRSSSEGKIQMLDSFLLSLGFLVTEKTVNHL
  LQQEGLKTFNCILHAVPREERKKFPLSEGMCHLMKDLARTLLTVGDYDQQVAISEALCRL
  TIKKSRDELVHKWFDDEVIAEAFKEIKDREFETDSRRFLNHLNNRLGDQRRVYSFPCIAA
  FADEHEMRKPADEKLEKFWIDFNLGSQSVTFYIDNAENTLWDSVTLPKEAVMNFSITETE
  KIKIFIIYLKKPMIISYKEVMKIEIHFDLQFNISQVSIQALGEDKQMLPDQTKISSELFS
  KSDKEDRESPSGLERETEQAEESTNMVEFMSAEDDRCLITLHLNDQSEPPVIGEPASDSH
  LQPVPPFGVPDFPQQPKSHYRKHLFSESNQDSSTSELSWTSNQKKKSLKSYSSRKKTRTR
  SNLRILPVFPPSSGSGHEKDQAKLLSPSEKEIPEQNNTTSPKTSEQKFQDSFAFLTAEDS
  AQKTELQDPHSLSELSSLKHSEDEEKPKIVNQESLTESTSLKHKLRNLEDKDIPEGSFAK
  SQQSRLEEEVAPGSPFSITEERELPEGISTSSLEVVPENLNGSAILPTFENFTKKRKRKY
  ELRYRKRPFNSENAKKAPDCLIKLLNQMQLFRLNKLERFQNLVLQELSSLKQDIQALEHL
  EKEVLEFWGKQSADLQSFCDLQVLRFNSTQTS
• Function: Oocyte-specific protein that localizes to centromeres at the dictyate stage and regulates the survival of primordial oocytes.
• Tissue Specificity: Expressed in the ovary (at protein level).

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Chronic obstructive pulmonary disease	DISQCIRF	Strong	Genetic Variation	[1]
Allergic rhinitis	DIS3U9HN	moderate	Genetic Variation	[2]
Phospholipid syndrome	DISPI49U	moderate	Genetic Variation	[3]

5 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of Synaptonemal complex protein 2-like (SYCP2L).	[4]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Synaptonemal complex protein 2-like (SYCP2L).	[5]
Hydroquinone	DM6AVR4	Approved	Hydroquinone decreases the expression of Synaptonemal complex protein 2-like (SYCP2L).	[6]
(+)-JQ1	DM1CZSJ	Phase 1	(+)-JQ1 increases the expression of Synaptonemal complex protein 2-like (SYCP2L).	[8]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Synaptonemal complex protein 2-like (SYCP2L).	[9]

1 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Synaptonemal complex protein 2-like (SYCP2L).	[7]

References

• [1] A genome-wide analysis of the response to inhaled 2-agonists in chronic obstructive pulmonary disease.Pharmacogenomics J. 2016 Aug;16(4):326-35. doi: 10.1038/tpj.2015.65. Epub 2015 Oct 27.
• [2] Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis.BMC Med Genomics. 2014 Aug 2;7:48. doi: 10.1186/1755-8794-7-48.
• [3] The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome.J Hum Genet. 2017 Sep;62(9):831-838. doi: 10.1038/jhg.2017.46. Epub 2017 Apr 20.
• [4] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [5] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [6] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [7] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [8] Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-beta-dependent mechanisms. Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):E4558-66.
• [9] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.